Skip to main content
Premium Trial:

Request an Annual Quote

Atossa Increases Anticipated Proceeds from Pending IPO

NEW YORK (GenomeWeb News) – Atossa Genetics, which refiled for an initial public offering earlier this year after withdrawing from an earlier attempt, today revised the estimate on how much the offering may garner.

In a Form S-1/A, the Seattle-based firm said that at the $5 midpoint of the expected price range for its shares, between $4 and $6, the IPO would bring in $5.4 million, or $6.2 million if underwriters exercise the overallotment option. Dawson James Securities is listed in its IPO filing as the underwriter.

When Atossa refiled its IPO in February, it said shares would fetch between $5 and $7, raising about $4.9 million, or $5.7 million if underwriters exercised their overallotment option.

The firm originally planned to offer 1 million shares. In August it increased the number of shares planned in the offering to 1.2 million shares, but lowered the price range to between $4 and $6. Last month it increased again the number of shares in the offering to 1.3 million shares.

The company also has revised the amount it needs to raise for approval to list on the Nasdaq Capital Market to at least $4 million in gross proceeds. Atossa previously said that it needed to raise at least $6 million, then increased the figure to $6.25 million.

Atossa plans to list its shares under ticker symbol "ATOS".

The Scan

Genetic Testing Approach Explores Origins of Blastocyst Aneuploidy

Investigators in AJHG distinguish between aneuploidy events related to meiotic missegregation in haploid cells and those involving post-zygotic mitotic errors and mosaicism.

Study Looks at Parent Uncertainties After Children's Severe Combined Immunodeficiency Diagnoses

A qualitative study in EJHG looks at personal, practical, scientific, and existential uncertainties in parents as their children go through SCID diagnoses, treatment, and post-treatment stages.

Antimicrobial Resistance Study Highlights Key Protein Domains

By screening diverse versions of an outer membrane porin protein in Vibrio cholerae, researchers in PLOS Genetics flagged protein domain regions influencing antimicrobial resistance.

Latent HIV Found in White Blood Cells of Individuals on Long-Term Treatments

Researchers in Nature Microbiology find HIV genetic material in monocyte white blood cells and in macrophages that differentiated from them in individuals on HIV-suppressive treatment.